Effect of Intravenous Interferon β-1a on Death and Days Free From Mechanical Ventilation Among Patients With Moderate to Severe Acute Respiratory Distress Syndrome A Randomized Clinical Trial

This RCT (n=301) concludes intravenous interferon β-1a administered for 6 days, resulted in no significant difference in a composite score that included death and number of ventilator-free days over 28 days (median, 10.0 vs 8.5 days for placebo, p=0.82).

Journal of the American Medical Association